Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2025
0mins
Source: Newsfilter
Market Growth and Impact: The abuse-deterrent opioid market is projected to grow significantly, with revenues expected to rise from USD 25.7 million in 2024 to USD 54.8 million by 2030, while the opioid crisis continues to lead to high rates of misuse and overdose deaths in the U.S.
Innovative Solutions: Companies like Nutriband and Pfizer are developing abuse-deterrent formulations and technologies aimed at reducing opioid misuse, including the Aversa™ Fentanyl patch and updated labeling for existing medications to mitigate abuse potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 26.180
Low
24.00
Averages
28.56
High
35.00
Current: 26.180
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Faces Challenges Yet Remains a Long-Term Investment Opportunity
- Long History: Founded in 1849, Pfizer has survived over a century in the highly competitive pharmaceutical industry, with a corporate ethos emphasizing resilience in adversity, which instills confidence in investors.
- Stock Price Decline: Pfizer's stock has dropped over 50% due to a retraction in pandemic-related vaccine demand, following a significant price spike, presenting a potential buying opportunity for long-term investors.
- Patent Expiration Risks: The company faces risks from the expiration of patents on key drugs, with several set to expire by 2028, leading to concerns about declining sales and investor apprehension.
- Innovation and Investment Opportunities: Despite challenges, Pfizer is actively developing new drugs, including vaccines and oncology treatments, with plans for up to 20 pivotal studies in 2026, indicating its long-term investment potential amidst industry dynamics.
See More
Investment Comparison: AbbVie vs. Pfizer
- AbbVie's Financial Performance: In FY 2025, AbbVie reported revenue of approximately $61.2 billion, an 8.6% increase year-over-year, with a net income of about $4.2 billion and a net margin of 6.9%, indicating successful integration of new products despite customer concentration risks.
- Pfizer's Market Position: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6% from the previous year, yet achieved a net income close to $7.8 billion with a net margin of 12.4%, demonstrating effective cost management amid patent expiration challenges.
- Risk Overview: AbbVie faces significant revenue concentration with 42% of its income reliant on two major products, contending with competition from biosimilars and pricing pressures, while Pfizer must navigate patent expirations and high R&D costs, highlighting their strategic differences.
- Valuation Comparison: AbbVie has a forward P/E ratio of 14.7x compared to Pfizer's 8.7x, indicating that Pfizer appears more attractive in terms of valuation, although AbbVie shows stronger growth prospects and business stability.
See More
Comparative Investment Analysis of AbbVie and Pfizer
- Revenue Growth Comparison: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.6% increase, showcasing its robust pipeline in immunology and oncology despite facing patent cliffs.
- Profit Performance: Pfizer generated nearly $62.6 billion in revenue during the same fiscal year, a slight decline of 1.6% from the previous year, yet net income was close to $7.8 billion, yielding a net margin of 12.4%, indicating effective cost management.
- Financial Health Status: AbbVie's debt-to-equity ratio stands at -21.1x, indicating total liabilities exceed shareholder equity, while Pfizer's ratio is approximately 0.8x, demonstrating stronger financial leverage and short-term solvency.
- Market Competition and Risks: AbbVie relies on two major products for 42% of its revenue, facing competition from biosimilars, while Pfizer must manage revenue declines due to multiple patent expirations, requiring investors to weigh each company's growth potential against stability.
See More
Pfizer Hosts Investor Webcast at Goldman Sachs Healthcare Conference
- Webcast Announcement: Pfizer Inc. will host a webcast on June 8, 2026, at 8:00 a.m. EDT, featuring CEO Albert Bourla, aimed at enhancing communication with investors and the public regarding the company's strategic direction.
- Access Information: Investors can access the webcast through Pfizer's website, with registration details available today, ensuring timely updates on the company's latest developments and initiatives.
- Replay and Transcript: The transcript and replay of the webcast will be available within 24 hours post-discussion and accessible for at least 90 days, enhancing transparency and meeting investor information needs effectively.
- Company Mission: Pfizer emphasizes its commitment to applying science and global resources to deliver innovative therapies, highlighting its leadership in healthcare product development and its goal to improve global healthcare access and quality through ongoing innovation and collaboration.
See More
Valuation Analysis of U.S. Healthcare Stocks
- Valuation Overview: Seeking Alpha's valuation grades highlight companies like Centene Corporation (CNC) and Pfizer (PFE) as attractive investment options among U.S. healthcare stocks with market caps over $10 billion, indicating their competitive positioning in the sector.
- Strong Valuation Metrics: Centene Corporation received an A+ valuation grade, while Pfizer earned an A, and BioMarin Pharmaceutical and Bristol-Myers Squibb received A- and A grades respectively, suggesting these companies are relatively undervalued in the market, potentially attracting investor interest.
- Comprehensive Assessment Method: The valuation grades are based on various financial metrics, including P/E, PEG, and EV/Sales ratios, factoring in both current and forward estimates to ensure investors have a holistic view of the companies' financial health.
- Healthcare Sector Outlook: With the ongoing growth in healthcare equipment, services, and pharmaceuticals, these high-rated stocks not only reflect current market value but may also provide substantial returns in future investments, drawing more capital into the sector.
See More
Eli Lilly's Retevmo Phase 3 Results Set New Oncology Standard
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 study demonstrates an 83% reduction in the risk of disease recurrence or death for Retevmo in early-stage RET fusion-positive non-small cell lung cancer patients, potentially establishing a new standard of care in the adjuvant setting, significantly enhancing the company's leadership in oncology.
- Survival Rate Improvement: The study also reports a 92% event-free survival rate at 24 months compared to 61% for placebo, a notable difference that not only boosts patient confidence in treatment but may also accelerate the adoption of genomic testing, further solidifying Lilly's market position in precision medicine.
- Strengthening Industry Trends: Lilly's success underscores the importance of precision medicine and biomarker-driven therapies in cancer treatment, likely attracting increased investor interest in other oncology companies with promising Phase 2 and Phase 3 catalysts, thereby driving innovation and growth across the industry.
- Future Outlook: With Lilly's breakthroughs in oncology, the market is keenly anticipating upcoming clinical data from other companies, including NeOnc Technologies and Olema Pharmaceuticals, which could further reshape investor perceptions of the oncology market.
See More
Pfizer Faces Challenges Yet Remains a Long-Term Investment Opportunity
- Long History: Founded in 1849, Pfizer has survived over a century in the highly competitive pharmaceutical industry, with a corporate ethos emphasizing resilience in adversity, which instills confidence in investors.
- Stock Price Decline: Pfizer's stock has dropped over 50% due to a retraction in pandemic-related vaccine demand, following a significant price spike, presenting a potential buying opportunity for long-term investors.
- Patent Expiration Risks: The company faces risks from the expiration of patents on key drugs, with several set to expire by 2028, leading to concerns about declining sales and investor apprehension.
- Innovation and Investment Opportunities: Despite challenges, Pfizer is actively developing new drugs, including vaccines and oncology treatments, with plans for up to 20 pivotal studies in 2026, indicating its long-term investment potential amidst industry dynamics.
See More
Investment Comparison: AbbVie vs. Pfizer
- AbbVie's Financial Performance: In FY 2025, AbbVie reported revenue of approximately $61.2 billion, an 8.6% increase year-over-year, with a net income of about $4.2 billion and a net margin of 6.9%, indicating successful integration of new products despite customer concentration risks.
- Pfizer's Market Position: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6% from the previous year, yet achieved a net income close to $7.8 billion with a net margin of 12.4%, demonstrating effective cost management amid patent expiration challenges.
- Risk Overview: AbbVie faces significant revenue concentration with 42% of its income reliant on two major products, contending with competition from biosimilars and pricing pressures, while Pfizer must navigate patent expirations and high R&D costs, highlighting their strategic differences.
- Valuation Comparison: AbbVie has a forward P/E ratio of 14.7x compared to Pfizer's 8.7x, indicating that Pfizer appears more attractive in terms of valuation, although AbbVie shows stronger growth prospects and business stability.
See More
Comparative Investment Analysis of AbbVie and Pfizer
- Revenue Growth Comparison: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.6% increase, showcasing its robust pipeline in immunology and oncology despite facing patent cliffs.
- Profit Performance: Pfizer generated nearly $62.6 billion in revenue during the same fiscal year, a slight decline of 1.6% from the previous year, yet net income was close to $7.8 billion, yielding a net margin of 12.4%, indicating effective cost management.
- Financial Health Status: AbbVie's debt-to-equity ratio stands at -21.1x, indicating total liabilities exceed shareholder equity, while Pfizer's ratio is approximately 0.8x, demonstrating stronger financial leverage and short-term solvency.
- Market Competition and Risks: AbbVie relies on two major products for 42% of its revenue, facing competition from biosimilars, while Pfizer must manage revenue declines due to multiple patent expirations, requiring investors to weigh each company's growth potential against stability.
See More
Pfizer Hosts Investor Webcast at Goldman Sachs Healthcare Conference
- Webcast Announcement: Pfizer Inc. will host a webcast on June 8, 2026, at 8:00 a.m. EDT, featuring CEO Albert Bourla, aimed at enhancing communication with investors and the public regarding the company's strategic direction.
- Access Information: Investors can access the webcast through Pfizer's website, with registration details available today, ensuring timely updates on the company's latest developments and initiatives.
- Replay and Transcript: The transcript and replay of the webcast will be available within 24 hours post-discussion and accessible for at least 90 days, enhancing transparency and meeting investor information needs effectively.
- Company Mission: Pfizer emphasizes its commitment to applying science and global resources to deliver innovative therapies, highlighting its leadership in healthcare product development and its goal to improve global healthcare access and quality through ongoing innovation and collaboration.
See More
Valuation Analysis of U.S. Healthcare Stocks
- Valuation Overview: Seeking Alpha's valuation grades highlight companies like Centene Corporation (CNC) and Pfizer (PFE) as attractive investment options among U.S. healthcare stocks with market caps over $10 billion, indicating their competitive positioning in the sector.
- Strong Valuation Metrics: Centene Corporation received an A+ valuation grade, while Pfizer earned an A, and BioMarin Pharmaceutical and Bristol-Myers Squibb received A- and A grades respectively, suggesting these companies are relatively undervalued in the market, potentially attracting investor interest.
- Comprehensive Assessment Method: The valuation grades are based on various financial metrics, including P/E, PEG, and EV/Sales ratios, factoring in both current and forward estimates to ensure investors have a holistic view of the companies' financial health.
- Healthcare Sector Outlook: With the ongoing growth in healthcare equipment, services, and pharmaceuticals, these high-rated stocks not only reflect current market value but may also provide substantial returns in future investments, drawing more capital into the sector.
See More
Eli Lilly's Retevmo Phase 3 Results Set New Oncology Standard
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 study demonstrates an 83% reduction in the risk of disease recurrence or death for Retevmo in early-stage RET fusion-positive non-small cell lung cancer patients, potentially establishing a new standard of care in the adjuvant setting, significantly enhancing the company's leadership in oncology.
- Survival Rate Improvement: The study also reports a 92% event-free survival rate at 24 months compared to 61% for placebo, a notable difference that not only boosts patient confidence in treatment but may also accelerate the adoption of genomic testing, further solidifying Lilly's market position in precision medicine.
- Strengthening Industry Trends: Lilly's success underscores the importance of precision medicine and biomarker-driven therapies in cancer treatment, likely attracting increased investor interest in other oncology companies with promising Phase 2 and Phase 3 catalysts, thereby driving innovation and growth across the industry.
- Future Outlook: With Lilly's breakthroughs in oncology, the market is keenly anticipating upcoming clinical data from other companies, including NeOnc Technologies and Olema Pharmaceuticals, which could further reshape investor perceptions of the oncology market.
See More
